Brussels / Nantes, July 30, 2007
During the first half of the year from January 1 until June 30, 2007, Eurofins achieved revenues of EUR 216.6m, which represents an increase of 44% compared with EUR 150.9m in H1/ 2006. Q2/ 2007 revenues were EUR 113.8m, a 41% increase over Q2/ 2006 (EUR 80.7m).
As in the first quarter, in addition to the organic growth this increase represents the ongoing effect of the consolidation of prior year acquisitions. Organic growth for the first half year was over 10%. Eurofins confirms its full year revenue objective of EUR 450m.
On the 26th July 2007 the Company paid its first ever dividend. This dividend of EUR 0.10 relates to the financial year 2006.
The Group achieved its EBITA budget in the first half of 2007. The full first half year results will be published on August 31, 2007.
For further information about Eurofins please visit www.eurofins.com or contact:
Phone: +32-2-769 7383
Notes for the editor:
Eurofins - a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.
With over 5,000 staff in more than 90 laboratories across 24 countries, Eurofins offers a portfolio of over 15,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both, its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on Euronext in the Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|EUROFINS SCIENTIF||Euronext Paris||419.65 (c)||0.47%||20 966|